144 related articles for article (PubMed ID: 36798261)
1. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant.
Nieto Y; Pasvolsky O; Bassett R; Ghanem S; Cuglievan B; Tewari P; Hosing C; Srour S; Ramdial J; Mahadeo K; Khazal S; Petropoulos D; Popat U; Qazilbash M; Kebriaei P; Champlin R; Shpall E
Res Sq; 2023 Feb; ():. PubMed ID: 36798261
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
Pasvolsky O; Bassett RL; Ghanem S; Cuglievan B; Tewari P; Hosing C; Srour S; Ramdial J; Mahadeo KM; Khazal S; Petropoulos D; Popat U; Qazilbash M; Kebriaei P; Champlin R; Shpall EJ; Nieto Y
BMC Cancer; 2023 Dec; 23(1):1258. PubMed ID: 38124057
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
4. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
9. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of pre- and post-transplantation
Ying Z; Mi L; Wang X; Zhang Y; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J
Chin J Cancer Res; 2017 Dec; 29(6):561-571. PubMed ID: 29353979
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
17. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
18. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China.
Xie Y; Wang X; Leng X; Zheng W; Ping L; Zhang C; Liu W; Deng L; Wu M; Song Y; Zhu J
Ann Hematol; 2020 Mar; 99(3):549-555. PubMed ID: 31980860
[TBL] [Abstract][Full Text] [Related]
20. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
